The financing will fund the planned Phase 3 trials for Apnimed’s lead candidate, AD109 (aroxybutynin + atomoxetine), that has the potential to be the first oral treatment for OSA. Enrollment for ...

anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 ...